Ratings Mithra Pharmaceuticals S.A.

Equities

MITRA

BE0974283153

Market Closed - Euronext Bruxelles Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
0.216 ^EUR	-1.82%		-.--%	-82.78%

May. 28	Mithra Delays AGM Amid Monetization Process	MT
Apr. 29	Mithra Pharmaceuticals to Postpone the Publication of Its Annual Report 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Most analysts recommend that the stock should be sold or reduced.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MITHRA PHARMACEUTICALS S.A.	-82.78%	16.13M	C+
CSL LIMITED	+0.82%	91.94B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-3.16%	38.74B	A-
UCB	+64.83%	26.66B	A
BIOMARIN PHARMACEUTICAL INC.	-13.98%	15.32B	C
INCYTE CORPORATION	-5.40%	13.3B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.65B	D+
ALTEOGEN INC.	+156.85%	10.37B	D
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.12B	B
SWEDISH ORPHAN BIOVITRUM AB	+2.32%	9.06B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders